Immunotherapy has changed the treatment paradigm for cancer, inducing durable responses in a subset of patients with previously refractory disease. However, current approaches are successful in only approximately 20% of cancers (so-called hot tumors). For the nearly 80% of cancers that are “cold” with weakly active immunity and few intratumoral T cells, immunotherapy has been largely ineffective.
According to Vinod P. Balachandran, MD, of Memorial Sloan Kettering Cancer Center, New York, pancreatic cancer is a model “cold” tumor that could inform immunotherapeutic principles needed for other treatment-resistant cancers. Read more . . .